Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
eNq9WF1v2jAUfedXRHlP0tB2ZVOg2li7IbUqo6BNe6lMcgEzx079wcd+/RxCV5gcdZi6EopE7Jx77Xt87pGTy1VOvAVwgRlt+3F44ntAU5ZhOm37o+F10PIvO41kjhboeVpTzwvj2PdSgoRo++VoOAZERfjj9uYz6O+B+52Gl7DxHFK5N09JTMKvSMxuUVHO8ZIFw5mXg5yxrO0XSm7eeomQXGfRWTL+SxQohSTavtkdnT+c7b5PohLsP1CVAH6D6NQICtQKM1WcA5VdJGHK+Lom31MrbCwGIJjiKfSRnPU5W+AMMmOICSICrIJMltk98AUBWQYxgkfzNBdW4GiOVgN47JmT/qhHu3Ilg5Mgvmidnp+dxfoXt6xC8Z2tMldBLyJKH+KLk7jZOo2ARmu9brYOciCIshyCJugHwVMKAS4wwbnK0diycn3GJSKOaoZFd592juJweHyRGxkWBUHrcC4K261CHOlh4Foc3C2kXMGQa7kies/+waeKkOjArEdbMXGUcalVXaaorNGU64HtRnQZlbCqr6idDMrVlosYxOvB/mbU3AL6akxwait4WpIUCDka9Or17u2k4hMSMOLutOI7phlbitfXoN2aO8q+2MioEbTgWfzQfN96F5+fWx+xn5pgNd3pSnFWQKTVCYtjRKdHJ+xYudGcNUM9MfaNyLpxUCxFBGo8VGCpS5qlT5bP2Tlwd8aqASPol6uhLXm+KeDr+81fIzTO2n/LbifaLjqBpmpt4ocTvzr/Tty14mZdmUlZiA9RtFwuwxkSgUB6l8IJf+OusNOm3Tl/J16g8kaVsjpKfVy1zMPqZ3sOX3ILxzrg7fdbp22MIbmCI2pRSbYzYe1dvb5WP9tfZ2n397TFXZiNVUUSM+rKJKmxEfG47qDrSq+5Foi7yQTX3MTU8jKJqlugTiOJyhugTuMP0UwSGg==
TELMbYafgZMRfECY
